Marton et al. 2019: Ibogaine and GDNF/BDNF Expression in a Rat Study

Definition

Definition: Preclinical (animal) study—not human clinical evidence. Marton S. et al. (2019) *Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits*, *Frontiers in Pharmacology* 10:193 (doi: 10.3389/fphar.2019.00193; PMID 30890941; PMC PMC6411846). Rats received acute intraperitoneal ibogaine 20 or 40 mg/kg (or vehicle); GDNF, BDNF, and NGF transcript/protein readouts were assayed in VTA, PFC, NAcc, and SN at 3 h and 24 h. At 24 h, 40 mg/kg selectively upregulated GDNF in VTA and SN (protein increase detected in VTA); both doses increased BDNF mRNA in NAcc/SN/PFC (VTA BDNF mRNA mainly at 40 mg/kg); proBDNF rose in NAcc; mature BDNF protein did not show significant regional increases in the assayed areas. This is mechanistic animal neuroscience—not human RCT evidence, not proof of clinical “brain resetting,” and not psychoactive IV ibogaine infusion efficacy in people. Clinical cardiac risk (QTc) remains relevant to any human use discussion even though this paper is not a cardiology study. Ibogaine is U.S. Schedule I / not approved for any indication. No cure claims.

Short answer

Marton and colleagues’ 2019 Frontiers in Pharmacology rat study found dose- and region-dependent increases in GDNF and BDNF-related expression after intraperitoneal ibogaine—especially GDNF in the VTA at 40 mg/kg. Preclinical neurotrophic changes are not human clinical proof and not psychoactive IV ibogaine infusion evidence. Label animal data clearly.

Why this paper matters

Marketing often leaps from “GDNF in the VTA” to “ibogaine rewires your brain / cures addiction.” The responsible approach: name the paper, keep the PRECLINICAL label loud, and refuse human IV proof inflation. Next steps still point to screening—not to DIY animal-dose math: /safety-and-screening → /apply. Related preclinical articles: /blog/belgers-2016-ibogaine-animal-meta-analysis, /blog/cameron-2020-tabernanthalog, /blog/ibogaine-18-mc-analog-preclinical.

What was studied

Key findings (plain language, no hype)

• Neurotrophic factor gene expression can rise a day after ibogaine in addiction-relevant circuits—in rats.
• GDNF in VTA at the higher dose aligns with earlier hypotheses linking GDNF to reduced alcohol self-administration in other rodent work (cited by authors)—still animal-to-animal inference.
• BDNF mRNA ≠ mature BDNF protein everywhere: transcript bumps did not automatically equal mature protein bumps in assayed regions; proBDNF changes add interpretive complexity.
• Dose matters: 20 vs 40 mg/kg were not interchangeable.
• Authors call for more research on whether these molecular changes explain anti-drug-seeking behavior.

Honest reading: Plausible plasticity mechanism class; zero permission to claim human clinical neuroplasticity proof or IV infusion efficacy.

How to read claims about this paper

Cardiac reminder (even on a preclinical page)

Human readers arrive via addiction/PTSD searches. Mechanism hope does not cancel QTc/fatality literacy (/blog/alper-herg-ibogaine-cardiac-mechanism, /blog/knuijver-2021-ibogaine-qtc-safety, /safety-and-screening). Cerebellar toxicity history in high-dose animals is a separate preclinical safety lane (/blog/ibogaine-purkinje-cerebellar-toxicity).

Route honesty & entity clarity

Intraperitoneal rodent dosing ≠ physician-supervised psychoactive IV ibogaine infusion in humans. Oral clinic literature ≠ this assay. Do not paste VTA GDNF figures into IV infusion ads.

Limits

How marketers misuse neurotrophic language

Phrases like “ibogaine releases GDNF,” “restores dopamine neurons,” or “opens critical periods like psychedelics” sometimes cite Marton 2019 or related reviews without saying rat, i.p., or hypothesis. Responsible writing names the species, dose, and endpoint class every time. Psychoplastogen analogies to ketamine/psilocybin dendritic work are research-frame comparisons—not interchangeable product claims for ibogaineinfusion.com.

Aftercare still beats mechanism slogans

Even if future human studies confirmed neurotrophic shifts, recovery would still need sleep, contingency management, trauma therapy, and relapse planning (/blog/ibogaine-aftercare-integration). Molecules do not replace psychosocial care.

Relationship to classic GDNF alcohol work

Earlier rodent alcohol self-administration studies (often cited alongside Marton) proposed VTA GDNF as a mediator of ibogaine’s anti-addictive persistence. Marton 2019 supplies region-resolved expression mapping that makes that hypothesis more anatomically specific—without converting it into a human outcomes trial. Keep the citation chain honest: animal behavior papers ≠ human IV infusion RCTs.

NGF signal

NGF mRNA rose broadly after 40 mg/kg in Marton’s maps. That widens the neurotrophic story beyond GDNF/BDNF slogans but also increases the temptation to over-claim “growth factor therapy.” Resist.

What this page is for in the content cluster

Use Marton 2019 when a reader asks “does ibogaine grow GDNF?” Answer: in rats, regionally, at certain doses, on mRNA/protein assays—yes, with caveats. Then pivot to human evidence tiers (observational OUD/PTSD papers) and cardiac screening. Mechanism articles should reduce magical thinking, not feed it.

Even careful mechanism literacy does not change Schedule I status or the need for ECG-capable supervision in any human pathway discussed on this site.

Next steps

Curious about mechanisms? Still start with human safety screening if considering treatment pathways: /safety-and-screening → /apply.

FAQ

Is this a human study? No. **PRECLINICAL** rat study.

DOI / PMID? doi **10.3389/fphar.2019.00193**; PMID **30890941**.

Does GDNF prove ibogaine cures addiction? No. Mechanistic animal signal only.

Was psychoactive IV ibogaine tested? No.

Can I scale 40 mg/kg rat i.p. to myself? No. Dangerous and unsupported.

Why mention cardiac risk on a rat page? Because human readers convert mechanism pages into treatment decisions; QTc risk remains clinically relevant.

Is ibogaine approved for medical use? No. Schedule I.

Where should screening start? /safety-and-screening → /apply.

Sources (selected)

1. Marton S. et al. *Front Pharmacol*. 2019. doi: 10.3389/fphar.2019.00193. PMID: 30890941.
2. Belgers M. et al. *Transl Psychiatry*. 2016. doi: 10.1038/tp.2016.71 (animal meta-analysis).
3. Cameron L.P. et al. *Nature*. 2021. doi: 10.1038/s41586-020-3008-z (analogue preclinical).
4. Alper K. et al. *Cardiovasc Toxicol*. 2016. doi: 10.1007/s12012-015-9311-5.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).

Medical disclaimer

Educational research synopsis only—not medical advice. This page summarizes preclinical animal data and is not evidence of human efficacy or safety for any ibogaine route. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some human contexts. Ibogaine is Schedule I in the United States and is not approved for any indication. Our IV ibogaine programs in Mexico and Gabon are not approved U.S. clinics. Next steps: /safety-and-screening, then /apply.

Marton 2019 is preclinical—not a cure claim and not psychoactive IV ibogaine infusion proof.